drug_type
RELEVANT_DRUG
intervention_type
Biological (autologous CAR T-cell therapy)
drug_description
An autologous, gene-edited CAR T-cell therapy targeting BCMA on myeloma cells. The CAR construct is integrated non-virally at the PD-1 locus to modulate/abrogate PD-1 signaling, aiming to reduce T-cell exhaustion and enhance antitumor activity. Ex vivo–expanded CAR T cells bind BCMA, activate cytotoxic responses, and kill BCMA+ malignant plasma cells while countering PD-1/PD-L1–mediated immunosuppression.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous gene-edited CAR T cells engineered with a BCMA-specific chimeric antigen receptor recognize and bind BCMA on myeloma cells, triggering cytotoxic killing of BCMA-positive malignant plasma cells. The CAR construct is integrated at the PD-1 locus to disrupt/modulate PD-1 signaling, reducing T-cell exhaustion and countering PD-1/PD-L1-mediated immunosuppression, thereby enhancing persistence and antitumor activity.
drug_name
PD1-BCMA-CART
nct_id_drug_ref
NCT05308875